AR118734A1 - Formulaciones y métodos de vectores de virus adenoasociados - Google Patents
Formulaciones y métodos de vectores de virus adenoasociadosInfo
- Publication number
- AR118734A1 AR118734A1 ARP200101106A ARP200101106A AR118734A1 AR 118734 A1 AR118734 A1 AR 118734A1 AR P200101106 A ARP200101106 A AR P200101106A AR P200101106 A ARP200101106 A AR P200101106A AR 118734 A1 AR118734 A1 AR 118734A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- methods
- adeno
- associated virus
- virus vectors
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 241000702421 Dependoparvovirus Species 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 2
- 239000012931 lyophilized formulation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836115P | 2019-04-19 | 2019-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118734A1 true AR118734A1 (es) | 2021-10-27 |
Family
ID=70617228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101106A AR118734A1 (es) | 2019-04-19 | 2020-04-17 | Formulaciones y métodos de vectores de virus adenoasociados |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220143115A1 (https=) |
| EP (2) | EP3955891B1 (https=) |
| JP (2) | JP7630443B2 (https=) |
| CN (1) | CN113993552A (https=) |
| AR (1) | AR118734A1 (https=) |
| ES (1) | ES3039486T3 (https=) |
| IL (1) | IL287214A (https=) |
| MX (1) | MX2021012564A (https=) |
| TW (2) | TW202332458A (https=) |
| WO (1) | WO2020214929A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012018628A1 (en) | 2010-07-26 | 2012-02-09 | Board Of Regents, The University Of Texas System | Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine |
| US9974850B2 (en) | 2013-01-25 | 2018-05-22 | Board Of Regents, The University Of Texas System | Immunogenic compositions and uses thereof |
| IL305149A (en) | 2016-07-26 | 2023-10-01 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
| TW202016314A (zh) | 2018-05-09 | 2020-05-01 | 美商拜奧馬林製藥公司 | 治療苯丙酮尿症之方法 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| TW202144575A (zh) * | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
| AU2021265768B2 (en) * | 2020-04-27 | 2023-03-30 | 4D Molecular Therapeutics Inc. | Adeno-associated variants, formulations and methods for pulmonary delivery |
| CA3190596A1 (en) * | 2020-08-07 | 2022-02-10 | Janssen Biotech, Inc. | Formulations for highly purified viral particles |
| US20240307553A1 (en) * | 2021-04-01 | 2024-09-19 | Pfizer Inc. | Pharmaceutical compositions containing adeno-associated viral vector |
| WO2022236008A1 (en) * | 2021-05-07 | 2022-11-10 | Board Of Regents, The University Of Texas System | Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules |
| EP4387641A4 (en) * | 2021-08-18 | 2025-07-09 | Ultragenyx Pharmaceutical Inc | RECOMBINANT AAV FORMULATIONS |
| US20230090654A1 (en) * | 2021-08-24 | 2023-03-23 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| WO2023177626A1 (en) * | 2022-03-14 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Lyophilized formulations of aav drug products |
| TW202404651A (zh) * | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| CN121548647A (zh) * | 2023-06-09 | 2026-02-17 | 4D分子治疗有限公司 | 腺伴随病毒制剂 |
| WO2025240411A1 (en) * | 2024-05-14 | 2025-11-20 | The Board Of Trustees Of The Leland Stanford Junior University | Cost-effective and user-friendly viral vector production methodology |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| DK1133316T3 (da) * | 1998-11-16 | 2009-05-25 | Introgen Therapeutics Inc | Adenovirus-formulering til genterapi |
| ATE226449T1 (de) * | 1998-12-03 | 2002-11-15 | Avigen Inc | Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| JP2003523320A (ja) * | 1999-09-29 | 2003-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途 |
| JP5118798B2 (ja) * | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| BRPI0511764B8 (pt) * | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| US7183969B2 (en) | 2004-12-22 | 2007-02-27 | Raytheon Company | System and technique for calibrating radar arrays |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| ES2751999T3 (es) | 2008-01-29 | 2020-04-02 | Applied Genetic Tech Corporation | Producción recombinante de virus adeno-asociados usando células BHK en suspensión |
| JP2011512156A (ja) | 2008-02-19 | 2011-04-21 | アムステルダム モレキュラー セラピューティクス ビー．ブイ． | 昆虫細胞におけるパルボウイルスｒｅｐ及びｃａｐタンパク質の発現の最適化 |
| EP2425000B1 (en) | 2009-04-30 | 2019-02-20 | The Trustees Of The University Of Pennsylvania | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
| US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| MX388221B (es) | 2013-04-20 | 2025-03-19 | Res Institute At Nationwide Children´S Hospital | ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2. |
| IL297919A (en) | 2013-07-22 | 2023-01-01 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| CN106232618A (zh) | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| AU2015320694B2 (en) | 2014-09-24 | 2021-11-11 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| JP6665466B2 (ja) | 2015-09-26 | 2020-03-13 | 日亜化学工業株式会社 | 半導体発光素子及びその製造方法 |
| WO2017070491A1 (en) | 2015-10-23 | 2017-04-27 | Applied Genetic Technologies Corporation | Ophthalmic formulations |
| BR112019009113A2 (pt) * | 2016-11-04 | 2019-07-16 | Baxalta Incorporated | formulações de vírus adenoassociado |
| WO2019212922A1 (en) | 2018-04-29 | 2019-11-07 | Regenxbio Inc. | Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles |
| CA3098565A1 (en) | 2018-04-29 | 2019-11-07 | Claire G. ZHANG | Scalable clarification process for recombinant aav production |
| US12070702B2 (en) | 2018-06-14 | 2024-08-27 | Regenxbio Inc. | Anion exchange chromatography for recombinant AAV production |
| EP3833745A1 (en) | 2018-08-10 | 2021-06-16 | REGENXBIO Inc. | Scalable method for recombinant aav production |
-
2020
- 2020-04-17 TW TW112114813A patent/TW202332458A/zh unknown
- 2020-04-17 TW TW109113112A patent/TW202103718A/zh unknown
- 2020-04-17 JP JP2021561002A patent/JP7630443B2/ja active Active
- 2020-04-17 EP EP20724998.8A patent/EP3955891B1/en active Active
- 2020-04-17 CN CN202080029377.3A patent/CN113993552A/zh active Pending
- 2020-04-17 WO PCT/US2020/028716 patent/WO2020214929A1/en not_active Ceased
- 2020-04-17 EP EP23186932.2A patent/EP4272817A3/en active Pending
- 2020-04-17 US US17/604,072 patent/US20220143115A1/en not_active Abandoned
- 2020-04-17 ES ES20724998T patent/ES3039486T3/es active Active
- 2020-04-17 MX MX2021012564A patent/MX2021012564A/es unknown
- 2020-04-17 AR ARP200101106A patent/AR118734A1/es not_active Application Discontinuation
-
2021
- 2021-10-12 IL IL287214A patent/IL287214A/en unknown
-
2023
- 2023-05-08 JP JP2023076620A patent/JP7669414B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES3039486T3 (en) | 2025-10-21 |
| EP4272817A3 (en) | 2024-01-24 |
| MX2021012564A (es) | 2022-01-18 |
| EP3955891A1 (en) | 2022-02-23 |
| TW202103718A (zh) | 2021-02-01 |
| WO2020214929A1 (en) | 2020-10-22 |
| EP4272817A2 (en) | 2023-11-08 |
| CN113993552A (zh) | 2022-01-28 |
| JP7669414B2 (ja) | 2025-04-28 |
| JP2023113623A (ja) | 2023-08-16 |
| IL287214A (en) | 2021-12-01 |
| US20220143115A1 (en) | 2022-05-12 |
| JP2022529002A (ja) | 2022-06-16 |
| TW202332458A (zh) | 2023-08-16 |
| JP7630443B2 (ja) | 2025-02-17 |
| CA3136939A1 (en) | 2020-10-22 |
| EP3955891C0 (en) | 2025-07-30 |
| EP3955891B1 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118734A1 (es) | Formulaciones y métodos de vectores de virus adenoasociados | |
| CL2020002200A1 (es) | Nuevos vectores del virus adeno-asociado (aav), vectores que tienen desaminación de capside reducida y sus usos. | |
| MX2025015023A (es) | Variantes de capsides de aav para liberacion intravitrea | |
| MX2023014041A (es) | Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion. | |
| CO2022016156A2 (es) | Redirección del tropismo de las cápsides de aav | |
| MX2017012097A (es) | Variantes de virus adenoasociado y métodos de uso de estas. | |
| MX2024004936A (es) | Variantes de capsides de aav y sus usos. | |
| CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
| MX2020008932A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| BR112018071180A2 (pt) | métodos de reforço potência biológica de baculovirus system-produzido vírus adeno-associado recombinante | |
| AR118465A1 (es) | Vectores de virus adenoasociados recombinantes | |
| MX2019009720A (es) | Metodos y composiciones para la transferencia de genes a traves de la vasculatura. | |
| CO2020016147A2 (es) | Composiciones de virus adenoasociado (aav) | |
| MX2022004146A (es) | Composición farmacéutica de vector de virus adenoasociado y métodos. | |
| MX2024014624A (es) | Variantes de capsides de aav y sus usos | |
| CL2023000264A1 (es) | Nuevos vectores virales adeno-asociados dirigidos al hígado | |
| MX2024009660A (es) | Variantes de capside de aav y usos de las mismas. | |
| WO2019191701A8 (en) | Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism | |
| MX2020005451A (es) | Capsides variantes de virus adenoasociados y uso para inhibir la angiogenesis. | |
| MX2016010649A (es) | Vector de virus adeno-asociado. | |
| CL2018003196A1 (es) | Cápsides variantes de virus adenoasociados y métodos de uso de estas. | |
| UY37620A (es) | Vacunas contra la gripe mediadas por aav novedosas | |
| UY36522A (es) | Ultracentrifugación analítica para la caracterización de partículas virales recombinantes | |
| WO2022103766A3 (en) | Engineered viral capsids and methods of use | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |